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Background: The gold standard for cobalamin deﬁciency treatment is administration of cobalamin by
intramuscular injection. The injection is painful and inconvenient, particularly for elderly persons.Key Words:
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Cobalamin might also be administered intranasally. Previous studies do not provide insight into the
pharmacokinetics of intranasal cobalamin administration in comparison with cobalamin injection.
Aim: To quantify the pharmacokinetics of intranasally and intramuscularly administered cobalamin to
determine if intranasal administration might be an alternative for intramuscular administration.
Methods: Ten inpatients and outpatients of a geriatrics unit were recruited and randomly assigned to
receive a single dose of 1000 μg cobalamin administered either by intranasal spray or intramuscular
injection (5 per group). Inclusion criteria were written informed consent, age 465 years, and a
cobalamin serum concentration o200 pmol/L. Total cobalamin serum concentrations were determined
10 times within 48 hours after administration. The differences in Cmax, Tmax, and AUC0–48 h per
administration route were statistically compared using ANOVA.
Results: The average Cmax was 1 nmol/L after intranasal and 38.5 nmol/L after intramuscular administration.
The average Tmax for intranasal and intramuscular administration was 42 minutes versus 342 minutes,
respectively, and the AUC0–48 h was 1.3 µmol/L/min versus 45.4 µmol/L/min, respectively. These values also
differed signiﬁcantly (Po0.05). The estimated bioavailability of the intranasal administration was 2%.
Conclusions: The pharmacokinetics of intranasal and intramuscular cobalamin administration in elderly,
cobalamin-deﬁcient patients differ signiﬁcantly. However, the estimated 2% bioavailability of cobalamin after
intranasal administration makes intranasal cobalamin administration a potentially interesting administration
route for elderly patients. Netherlands Trial Registry identiﬁer: NTR 3005.
& 2014. The Authors. Published by Elsevier Inc. All rights reserved. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Cobalamin deﬁciency in human beings may take 3 to 4 years to
develop due to the large cobalamin stores in the liver. Never-
theless, approximately 10% to 15% of the population aged 65 years
and older has cobalamin (vitamin B12) deﬁciency. An even higher
prevalence of 30% to 40% is reported for malnourished and sick
elderly people.1 Cobalamin serves as a cofactor for methionine
synthase and L-methylmalonyl-coA mutase. People with cobala-
min deﬁciency may experience megaloblastic anemia, subacute
combined degeneration of the spinal cord, peripheraler Inc. All rights reserved. This is a
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ans).polyneuropathy, cognitive impairment, and mental changes.2
Cobalamin deﬁciency is due to malabsorption of food-bound
cobalamin and/or insufﬁcient dietary intake. Food-bound cobala-
min is released by pepsin in the acidic environment in the
stomach. Subsequently, cobalamin is bound to intrinsic factor in
the duodenum. The cobalamin-intrinsic factor complex then binds
to the ileal endocytic cubam receptor. The cubam receptor consists
of 2 proteins: cubulin and amnionless. Together these proteins
take part in the endocytosis of the intrinsic factor-cobalamin
complex, which is followed by degradation of intrinsic factor in
lysosomes and the release of cobalamin into plasma in complex
with transcobalamin II. Cobalamin malabsorption can therefore be
caused by lack of intrinsic factor, decreased pepsin or acid
secretion, or other defects in the cobalamin uptake system.3,4
Repeated administration of cobalamin by way of intramuscular
injection has been the gold standard for cobalamin deﬁciencyn open access article under the CC BY-NC-ND license
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several disadvantages. Injections are painful; injection-related
adverse reactions (such as intramuscular hematoma) may occur,
especially in elderly persons who are frequently treated with
anticoagulant medication; and health care professionals are usu-
ally needed to administer the injections. The latter increases the
burden of the treatment considerably. A more convenient and
safer treatment would be advantageous to both patients and the
health care system in general.5
Food-bound cobalamin is actively absorbed. In contrast, crys-
talline cyanocobalamin administered via capsules is absorbed by
way of passive diffusion. Although approximately only 1% of an
oral dose of crystalline cyanocobalamin is absorbed, oral admin-
istration of cyanocobalamin is effective in normalizing serum
cobalamin levels.6,7 Oral treatment might not be an option in
patients who have an absorption disorder or are unable to take
oral medication.8–10 Intranasal administration of cobalamin could
be a suitable alternative to both cobalamin injections and oral
administration in elderly patients.
Absorption of intranasally administered cobalamin has been
demonstrated in studies.11–14 However the results of those studies
do not provide insight into the pharmacokinetics of intranasally
administered cobalamin in elderly, cobalamin-deﬁcient patients or
in comparison with cobalamin injection. Insight into the pharma-
cokinetics is necessary to determine if intranasal administration
could be an alternative to intramuscular administration in elderly
patients. Also, insight into the pharmacokinetics could be used to
develop a dosing regimen. The objective of our pilot study was to
quantify the pharmacokinetics of intranasally and intramuscularly
administered cobalamin in elderly, cobalamin-deﬁcient patients to
determine if intranasal administration might be an alternative for
intramuscular administration.Materials and Methods
Design, setting, and study population
Ours was a randomized, open, comparative pilot study con-
ducted between September 2011 and January 2012 in Haarlem, the
Netherlands. Patients were recruited from the in- and outpatient
geriatrics department of the Kennemer Gasthuis, a teaching hospital
with a total of 450 beds of which 15 are geriatrics beds (3250
geriatric outpatient visits a year). Cobalamin serum concentration
measurements are part of standard care at this clinic. Eligible
patients were aged 65 years or older who had a cobalamin serum
concentration o200 pmol/L. Patients also had to be able to give
written informed consent. Patients with chronic rhinitis, a running
nose, or concomitant use of intranasally administered medication
were excluded from study participation to minimize possible
inﬂuences on intranasal absorption. In addition, patients who were
hemodynamically instable, had clinically signiﬁcant infections, or
were severely malnourished were excluded from participation for
ethical reasons. Simpliﬁed Nutritional Appetite Questionnaire was
used to determine a patient’s nutritional status.15 Patients with a
score of 3 were excluded. Patients with a glomerular ﬁltration rate
r20 mL/min/1.73 m2 were also excluded from study participation,
because cobalamin is exclusively excreted through the kidneys. The
study protocol (NL33450.029.11) was approved by the Medical
Ethics Committee of the Vrije Universiteit Amsterdam and the
Kennemer Gasthuis Haarlem.
Randomization and intervention
Patients were randomly assigned to 1 of the 2 study groups, to
receive a single dose of 1000 μg cobalamin administered byintranasal spray or by intramuscular injection. A research nurse
administered either 2 mL of a 500 μg/mL hydroxocobalamin
solution for injection (Hydrocobamin, Nycomed BV, Hoofddorp,
the Netherlands) in the muscle of the upper left or right arm, or
1 puff (0.1 mL) 500 μg cyanocobalamine (Nascobal, Par Pharma-
ceutical Companies Inc, Woodcliff Lake, New Jersey) in each
nostril. The intranasal spray was primed before each administra-
tion. Blood samples were obtained at 0, 15, 30, 60, 120, 240, 480,
1440 (24 hours), and 2880 minutes (48 hours) following admin-
istration. These blood samples were drawn using an intravenous
cannula inserted into a forearm vein. The cannula was inserted in
the arm not used for injection if the patient received the cobala-
min by way of intramuscular injection.
Analysis
Total cobalamin serum concentrations were determined using a
competitive immunoassay vitamin B12 kit with a measuring range
between 22 and 1476 pmol/L (Roche Diagnostics GmbH, Man-
nheim, Germany) on a Roche Modular Analytics E170 immuno-
assay analyzer (Roche Diagnostics GmbH, Mannheim, Germany).
The mean coefﬁcient of variation in human serum of this assay is
1.9% for repeatability and 4.7% for intermediate precision. Samples
were diluted with Elecsys Diluent Universal (Roche Diagnostics
GmbH, Mannheim, Germany) in case the cobalamin serum con-
centration exceeded the upper range of the assay.
A concentration-time graph was constructed for each patient
using PK Solutions (version 2.0, Summit Research Services, Montrose,
California). For each patient Cmax, Tmax, and AUC0–48 h were deter-
mined using PK Solutions. The average of Cmax, Tmax, and AUC0–48 h
for the group receiving cobalamin intranasally and the group
receiving cobalamin intramuscularly were also calculated using PK
Solutions. Bioavailability of the intranasal administration was esti-
mated by dividing the mean AUC0–48 h after intranasal administra-
tion by the mean AUC0-48 h after intramuscular administration.
In our pilot study a sample size of 10 was presumed sufﬁcient
to establish if intranasal administration could be a potential
alternative for intramuscular administration in elderly patients.
Data were tested for deviations from a normal distribution.
Subsequently differences between both groups of patients in Cmax,
Tmax, and AUC0–48 h were tested for signiﬁcance using ANOVA. The
ANOVA was done using PASW Statistics (version 18, IBM-SPSS Inc,
Armonk, NY). A P value r 0.05 was considered statistically
signiﬁcant.Results
Thirteen patients gave written informed consent. Three patients
were excluded from the ﬁnal analysis. One patient did not receive
the study medication because the intravenous cannula could not be
inserted. Analyses of blood samples of 2 patients failed due to
incorrect handling. Ten patients were therefore included in the ﬁnal
analysis. The mean age of patients was 81 years (range ¼ 70–91
years), the mean weight was 76 kg (range ¼ 60–93 kg), and the
mean baseline cobalamin serum concentration was 165 pmol/L
(range ¼ 100–250 pmol/L). Five patients received cobalamin by
way of intranasal spray and 5 patients by way of intramuscular
injection. Between the intranasal and intramuscular groups there
were no signiﬁcant differences in mean baseline cobalamin serum
concentration, body mass index, and age (Table I).
The concentration-time graphs of the different patients follow-
ing intranasal and intramuscular administration are presented in
Figure 1. Similar overall changes in serum cobalamin concentra-
tion over time were determined among patients in the intranasal
administration group (Figure 1A). The Cmax varied between 0.5 and
Table I
Baseline characteristics of patients receiving intranasal and intramuscular cobala-
min administration.
Intranasal
administration (range)
Intramuscular
administration (range)
Cobalamin concentration
(pmol/L)
160 (100-200) 170 (110-250)
Body mass index 26 (23.5-32.9) 24 (23.5-24.9)
Age, y 83 (78-91) 78 (70-84)
Gender, male/female 4/1 2/3
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among the patients with minor differences in Tmax. The AUC0-48 h
among patients varied between 0.67 and 2 μmol/L/min.
Patients in the intramuscular administration group did not show
similar overall changes in serum cobalamin concentration over time
(Figure 1B). The maximum concentration in this group also varied2200
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Figure 1. Concentration-time graphs of patients receiving 1000 μg cobabetween 22 and 72 nmol/L. Contrary to the intranasal administra-
tion group, the Tmax varied considerably among these patients,
ranging between 60 and 480 minutes. Patients in this group had
AUC0-48 h that varied noticeably between 8.7 and 76 μmol/L/min.
The average concentration-time graphs after intranasal and
intramuscular administration are presented in Figure 2. After
intranasal administration a signiﬁcantly (P o 0.05) lower Cmax
(ie, 1 vs 38.5 nmol/L) was determined compared with intra-
muscular administration. Cobalamin absorption was signiﬁcantly
(P o 0.05) faster following intranasal administration (ie, Tmax
42 vs 324 minutes, respectively). The bioavailability of cobalamin
after intranasal administration was estimated to be 2% compared
with intramuscular administration. AUC0-48 h was signiﬁcantly
(P o 0.05) smaller after intranasal compared with intramuscular
administration. Both the intranasal and intramuscular administra-
tions were well tolerated. No adverse events were reported in
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Figure 2. Average concentration time curves following intranasal and intramuscular cobalamine administration, respectively. Following intranasal administration, mean
(SD) Tmax was 42 (16) minutes, Cmax was 1.0 (0.6) nmol/L, and AUC0-48 hours was 1.3 (0.6) µmol/L/min. Following intramuscular administration, mean (SD) Tmax was 324 (215)
minutes, Cmax was 38.5 (20.5) nmol/L, and the AUC0-48 hours was 61 (19) µmol/L/min.
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In our pilot study, signiﬁcant pharmacokinetic differences
between intranasal and intramuscular cobalamin administration
in elderly, cobalamin-deﬁcient patients were established. After
intranasal administration the Cmax and AUC0-48 h were lower, and
Tmax was reached faster, compared with intramuscular adminis-
tration. The estimated cobalamin bioavailability after intranasal
administration was 2%.
Our study has several limitations. Only 10 frail elderly patients
were included because of the invasive nature of the study. Also, a
crossover design was considered unethical. Because cobalamin
levels can be raised for a long period of time—especially after
intramuscular injection—a wash-out period of 2 to 3 months
would have been necessary in a crossover design to rule out
inﬂuences from 1 administration upon the other. During this
period patients would not have been treated properly for their
cobalamin deﬁciency.
Furthermore, 2 different cobalamin forms (ie, hydroxocobala-
min [injection] and cyanocobalamin [nasal spray]) were used in
our study. Cyanocobalamin intranasal spray was used because
there was no registered hydroxocobalamin intranasal spray
available. Although the molecular structures of hydroxocobala-
min and cyanocobalamin are almost identical, hydroxocobalamin
is believed to be better retained by the body due to better
receptor binding. A better availability to cells has not been
established and both forms are registered for cobalamin deﬁ-
ciency treatment.16,17
The immunoassay used to measure cobalamin serum concen-
trations measures total serum cobalamin—both protein-bound and
free cobalamin—and does not differentiate between hydroxocoba-
lamin and cyanocobalamin. The bioavailability of the cobalamin
injection is assumed to be 100%. The bioavailability of intranasally
administered cobalamin in our study was estimated to be 2%,
which is comparable to previous studies, in which a bioavailability
of 2% and 5% were found.11
In our study, vast interpatient differences were identiﬁed
within both the intranasal and the intramuscular administration
group. Interpatient variability was expected for intranasal admin-
istration due to differences in nasal mucosa and mucociliary
clearance. The large interpatient differences found in the intra-
muscular administration group were unexpected. As can be seenin Figure 1B, cobalamin absorption following intramuscular
administration differed among the patients. This might have been
caused by changes in muscle mass due to aging.18
Here, a serum cobalamin cut-off value of 200 pmol/L was used
to identify a cobalamin deﬁciency. Generally a serum cobalamin
concentration o148 pmol/L is used to identify cobalamin deﬁ-
ciency. Because elderly persons may already be cobalamin deﬁcient
while having a cobalamin serum concentration 4148 pmol/L,
other serum cobalamin cut-off values for elderly persons have been
proposed.19–21
An average Cmax of 38,500 pmol/L was established after intra-
muscular cobalamin administration. The therapeutic cobalamin
serum concentration range is generally considered to be between
148 and 664 pmol/L. The high cobalamin serum concentrations
following intramuscular cobalamin administration seem to be of
little clinical signiﬁcance. In several studies daily oral administra-
tion of even low cobalamin doses have been shown to be effective
in normalizing cobalamin serum concentrations.22–26 Some stud-
ies have also demonstrated oral cobalamin administration to be at
least as effective as intramuscular administration for treatment of
cobalamin deﬁciency.27,28 Like intranasal administration, the max-
imum concentration after oral administration is lower compared
with intramuscular administration. In a recent study a Cmax of
1000 pmol/L was reached after a single oral cobalamin dose of
1000 μg; this is comparable to the average Cmax of 1040 pmol/L
after intranasal administration established in this study.29 The
bioavailability of cobalamin after oral administration is approx-
imately 1 %, which is also comparable to the bioavailability after
intranasal administration found in this study.
We compared intranasal cyanocobalamin and intramuscular
hydroxycobalamin administrations to gain insight into the phar-
macokinetics, to determine if intranasal cyanocobalamin admin-
istration could be an alternative for intranasal administration.
Absorption of intranasally administered cobalamin has been
examined in healthy elderly volunteers and in patients with ileal
resections or Crohn’s disease. Reproducible nasal hydroxocobala-
min absorption has been shown in these studies.11,12 Similarly,
our study shows reproducible nasal absorption of a single dose of
1000 μg cyanocobalamin in elderly, cobalamin-deﬁcient patients.
Also, the Tmax of 42 minutes determined in our study is com-
parable to the Tmax of 35 minutes found in healthy elderly
volunteers.
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Despite its limitations our study shows that there are signiﬁ-
cant pharmacokinetic differences between intranasal and intra-
muscular cobalamin administration. The bioavailability of 2% after
intranasal administration is comparable to the bioavailability after
oral administration. Intranasal cobalamin administration was well
tolerated and no adverse events were reported. Hence, intranasal
administration seems a potentially interesting alternative to intra-
muscular cobalamin administration. Additional research is needed
to assess the pharmacokinetics of repeated intranasal cobalamin
administration to determine an intranasal dosing regimen. A
clinical study will also have to demonstrate efﬁcacy and safety of
repeated intranasal cobalamin administration in cobalamin-
deﬁcient elderly persons.Acknowledgments
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